Literature DB >> 2423159

Biology of human megakaryocyte factor V.

A M Gewirtz, M Keefer, K Doshi, A E Annamalai, H C Chiu, R W Colman.   

Abstract

To learn more about human megakaryocyte coagulation cofactor V (FV), we studied the expression of this protein in normal bone marrow megakaryocytes and in megakaryocytes cloned from their colony-forming unit in FV-depleted plasma clot cultures. Mouse monoclonal antibodies directed against either the light chain or an activation peptide of human FV and a rabbit polyclonal, monospecific FV antiserum were used as probes for these experiments in conjunction with a variety of immunochemical detection techniques. All morphologically recognizable megakaryocytes were shown to contain FV. The origin of this protein appeared to be both from FV bound to the cell as well as from endogenous FV in the majority of cells examined. The existence of a population of small bone marrow mononuclear cells that simultaneously expressed platelet glycoproteins and FV was also noted. Such cells represented approximately 70% of all small cells positive for platelet glycoproteins. In contrast, only about 40% of megakaryocyte colonies cloned in FV-deficient medium contained cells with immunochemically detectable FV. FV expression was most clearly demonstrated in large cells in the colonies, whereas smaller, presumably less mature cells labeled weakly or not at all. Synthesis of FV by human megakaryocytes was documented using elutriation-enriched cells incubated in 35S-methionine-containing medium. Megakaryocyte lysates and medium conditioned by these cells were subjected to immunoaffinity column purification. Column eluates analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography revealed radioactive bands comigrating with the heavy and light chains of thrombin-activated FV. These studies suggest that human megakaryocytes both bind and synthesize FV. Expression of these traits appears to be related to cell maturation, with binding ability appearing earlier than the ability to synthesize this protein. Finally, although the ability to bind FV appears to be universal among megakaryocytes, our culture data suggest that synthesis may be a restricted, or constitutively expressed property of these cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2423159

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Electron microscopy of human factor V and factor VIII: correlation of morphology with domain structure and localization of factor V activation fragments.

Authors:  W E Fowler; P J Fay; D S Arvan; V J Marder
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  Incorporation of a circulating protein into megakaryocyte and platelet granules.

Authors:  P J Handagama; J N George; M A Shuman; R P McEver; D F Bainton
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

3.  Blood coagulation factors V and VIII: Molecular Mechanisms of Procofactor Activation.

Authors:  Mettine H A Bos; Rodney M Camire
Journal:  J Coagul Disord       Date:  2010-07-01

Review 4.  The molecular basis of factor V and VIII procofactor activation.

Authors:  R M Camire; M H A Bos
Journal:  J Thromb Haemost       Date:  2009-09-18       Impact factor: 5.824

5.  Hematopoietic placental protein 14. An immunosuppressive factor in cells of the megakaryocytic lineage.

Authors:  D M Morrow; N Xiong; R R Getty; M Z Ratajczak; D Morgan; M Seppala; L Riittinen; A M Gewirtz; M L Tykocinski
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

6.  Inhibition of human megakaryocytopoiesis in vitro by platelet factor 4 (PF4) and a synthetic COOH-terminal PF4 peptide.

Authors:  A M Gewirtz; B Calabretta; B Rucinski; S Niewiarowski; W Y Xu
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

7.  A case of coagulation factor V deficiency complicated with intracranial hemorrhage.

Authors:  S G Yoon; S T Cho; S K Park; J H Won; S H Baick; D S Hong; H S Park
Journal:  Korean J Intern Med       Date:  1997-01       Impact factor: 2.884

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.